Press release
Cryptococcosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals
"Cryptococcosis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cryptococcosis Therapeutics Market.
The report provides a detailed description of the Cryptococcosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Cryptococcosis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/cryptococcosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Cryptococcosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Cryptococcosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cryptococcosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Cryptococcosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Cryptococcosis treatment market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Cryptococcosis Therapeutics Domain:
https://www.delveinsight.com/report-store/cryptococcosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Cryptococcosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Cryptococcosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Cryptococcosis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/cryptococcosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Cryptococcosis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Cryptococcosis. Currently, Matinas BioPharma is leading the therapeutics market with its Cryptococcosis drug candidates in the most advanced stage of clinical development.
Cryptococcosis Companies in the Therapeutics Market Include:
• Matinas BioPharma
• Mycovia Pharmaceuticals
• Aparna Biosciences
• FUJIFILM Toyama Chemical
• TGV Therapeutics
• Amplyx Pharmaceuticals
And Many Others
Emerging and Marketed Cryptococcosis Therapies Covered in the Report Include:
MAT 2203: Matinas BioPharma
MAT2203 is an orally-administered formulation of amphotericin B (a broad spectrum fungicidal agent) utilizing Matinas' proprietary lipid nano-crystal ("LNC") delivery technology platform. The Company's LNC delivery platform utilizes lipid nano-crystals which can encapsulate small molecules, nucleic acid polymers such as oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Get an in-depth Assessment of the Emerging Therapies and Cryptococcosis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/cryptococcosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Cryptococcosis Current Treatment Patterns
4. Cryptococcosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cryptococcosis Late-Stage Products (Phase-III)
7. Cryptococcosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cryptococcosis Discontinued Products
13. Cryptococcosis Product Profiles
14. Cryptococcosis Companies
15. Cryptococcosis Drugs
16. Dormant and Discontinued Products
17. Cryptococcosis Unmet Needs
18. Cryptococcosis Future Perspectives
19. Cryptococcosis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/cryptococcosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cryptococcosis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals here
News-ID: 3073892 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Cryptococcosis
Cryptococcosis Market Future Prediction Report By 2031
Cryptococcosis Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market dynamics.
Download…
Cryptococcosis Market Opportunities, Business Forecast To 2029
According to Precision Business Insights (PBI), latest report cryptococcosis market was valued at USD 5,273.5 million in 2022, growing at an 4.5% CAGR from 2023 to 2029. The market for cryptococcosis is driven by the prevalence of low immunity among a large portion of the population brought on by smoking, alcohol use, poor nutrition, rising disease prevalence, and stress, which makes it easier to contract the disease. Furthermore, an increase…
Cryptococcosis Market to Develop Rapidly by 2031, TMR Study
The global cryptococcosis market is estimated to attain a valuation of US$ 4.9 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.3% during the forecast period, 2019 to 2027.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders…
Cryptococcosis Market Growth Opportunities from 2022 - 2031, TMR Study
The global cryptococcosis market is estimated to attain a valuation of US$ 4.9 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.3% during the forecast period, 2019 to 2027.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders…
Lupin Limited launched Ancobon Capsules’ for cryptococcosis treatment market
The growing prevalence of cryptococcus disease is escalating the growth of the cryptococcosis treatment market. The Centers for Disease Control and Prevention (CDC) states that around 1 million cryptococcosis cases arise throughout the globe, and it is anticipated that annually, the number of deaths associated with cryptococcosis is around 650,000. Most of the cases are reported among patients with complex HIV disease. Moreover, rising count of people being contaminated by…
Cryptococcosis Treatment Market Opportunity Analysis, 2018-2026
Cryptococcosis or cryptococcal disease is a fungal disease, which in severe cases can be fatal. It is caused by either Cryptococcus neoformans or Cryptococcus gattii. Cryptococcosis is said to be acquired by inhaling contagious propagule from surroundings. Even though the accurate character of the contagious propagule is not known, the primary theory is the basidiospore produced in the course of sexual or asexual reproduction is the cause. Cryptococcosis disease symptoms…
